메뉴 건너뛰기
Cancer
Volumn 113, Issue 9, 2008, Pages 2376-2378
Targeted therapy in prostate cancer - Are we our own worst enemy?
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; DOCETAXEL; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PLACEBO;
EID: 55549123526     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23865     Document Type: Editorial
Times cited : (7)
References (7)
  • 1
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 2
    • 0036283452 scopus 로고    scopus 로고
    • Endothelin-1 as a target for therapeutic intervention in prostate cancer
    • Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs. 2002;20:173-182.
    • (2002) Invest New Drugs , vol.20 , pp. 173-182
    • Kopetz, E.S.1    Nelson, J.B.2    Carducci, M.A.3
  • 3
    • 35648968713 scopus 로고    scopus 로고
    • A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    • Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-1966.
    • (2007) Cancer , vol.110 , pp. 1959-1966
    • Carducci, M.A.1    Saad, F.2    Abrahamsson, P.A.3
  • 4
    • 55549112219 scopus 로고    scopus 로고
    • Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone-refractory prostate cancer
    • Nelson JB, Love W, Chin JL, et al. Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone-refractory prostate cancer. Cancer. 2008;113:2478-2487.
    • (2008) Cancer , vol.113 , pp. 2478-2487
    • Nelson, J.B.1    Love, W.2    Chin, J.L.3
  • 5
    • 30344449974 scopus 로고    scopus 로고
    • ZD4054: A specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease [abstract]
    • Curwen JO, Wilson C. ZD4054: a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease [abstract]. Eur J Cancer. 2002;38:S102.
    • (2002) Eur J Cancer , vol.38
    • Curwen, J.O.1    Wilson, C.2
  • 6
    • 55549086264 scopus 로고    scopus 로고
    • Impact of the specific endothelial A receptor antagonist ZD4054 on overall survival and bone metastases in patients with hormone-resistant prostate cancer: Results of a phase II trial [abstract]
    • Presented at the, San Francisco, California, February 14-16, Abstract 7
    • Dawson N, Phung D, Morris T, et al. Impact of the specific endothelial A receptor antagonist ZD4054 on overall survival and bone metastases in patients with hormone-resistant prostate cancer: results of a phase II trial [abstract]. Presented at the ASCO 2008 Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008. Abstract 7.
    • (2008) ASCO 2008 Genitourinary Cancers Symposium
    • Dawson, N.1    Phung, D.2    Morris, T.3
  • 7
    • 33746316497 scopus 로고    scopus 로고
    • Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone [abstract]
    • Presented at the, Nashville, Tennessee, September 23-27, Abstract 1213a
    • Mohammad K, McKenna C, Mison A, et al. Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone [abstract]. Presented at the American Society for Bone and Mineral Research 27th Annual Meeting, Nashville, Tennessee, September 23-27, 2005. Abstract 1213a.
    • (2005) American Society for Bone and Mineral Research 27th Annual Meeting
    • Mohammad, K.1    McKenna, C.2    Mison, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.